OTS - Debiopharm & Dexa Medica launch triptorelin collaboration to bring new hope to women with endometriosis (part 1)
2021. October 07. 09:00
Lausanne, Switzerland - Tangerang, Indonesia, 7 October, 2021
(APA/OTS) - Debiopharm (www.debiopharm.com), a Swiss-based, global
biopharmaceutical company, and Dexa Medica, a leading Indonesian
pharmaceutical company, today announced the Indonesian launch of
triptorelin for the treatment of women with gynecological
disorders, particularly endometriosis. Triptorelin, marketed under
the brand name Pamorelin® is one of the most common
gonadotropin-releasing hormone agonists (GnRH-a) used worldwide to
help women with endometriosis reduce pain-related symptoms by
inducing a low estrogen status. Clinical research revealed pain
symptom improvement with Pamorelin® as being confirmed by the
reduction in the volume of endometriotic nodules during treatment
vs. placebo.(1)
Endometriosis is a chronic, debilitating disease involving
long-term inflammation and the presence of functional endometrial
glands and stroma outside the uterine cavity. Having serious
consequences for general and reproductive health, pelvic
endometriosis has a high incidence estimated between 10% of
reproductive aged women worldwide (approximately 190 million) and
remains underdiagnosed.(2) Furthermore, up to 49% of women
reporting chronic pelvic pain are known to suffer from
endometriosis.(2) Dexa Medica's nation-wide launch and distribution
of triptorelin, as Debiopharm's exclusive Indonesian licensee, will
help patients in the region gain access to the pain-relieving
benefits of hormone suppression with Pamorelin®.
"We naturally recognized that Dexa Medica was the ideal company
to pioneer triptorelin access to patients in Indonesia. Their high
standards of ethics, regional pharmaceutical leadership, and strong
commercialization track record and reputation align well with
Debiopharm's values," stated Fabrice Paradies, Senior Director,
Business Development & Global Commercial Alliances, Debiopharm.
"This alliance with Dexa Medica is highly valued as they are
dedicated to covering Indonesia, with over 270 million people the
largest country in Southeast Asia, having the capability to manage
the logistic complexity to provide treatment access to patients in
a country having a population of over 270 million on nearly 1,000
inhabited islands."
"Medical management of endometriosis primarily aims to delay
disease progression and alleviate symptoms. Aside from infertility,
the most debilitating symptoms in women with endometriosis are pain
manifested as severe dysmenorrhea, dyspareunia, chronic pelvic
pain, dysuria or dyschezia. These symptoms also tend to worsen
with repeated menstrual cycles," stated Raymond R. Tjandrawinata,
Ph.D., Director of Business and Scientific Development PT Dexa
Medica.
"We, as a leading pharmaceutical company in Indonesia, are very
proud and excited to collaborate with a globally reputed company,
Debiopharm, to market quality products such as Triptorelin which
helps Indonesians to overcome health problems related to
endometriosis. Although there is currently no definitive data, the
general prevalence is around 3% - 10%, especially in women of
reproductive age in Indonesia," stated Commercial Director PT Dexa
Medica, V Hery Sutanto.
About Pamorelin®
Pamorelin® (triptorelin) is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH), the only agonist of its kind
that differs from natural GnRH by a single amino acid and works by
decreasing the amount of certain hormones in the body. Pamorelin®
helps women to maintain estradiol suppression, an important factor
in the management and relief of chronic pain associated with
endometriosis. When the basic activation process of the GnRH
receptor is interrupted, this initiates a cascade of events leading
to the fall in pituitary luteinizing hormone (LH) and follicle
stimulating hormone (FSH) secretion, causing a low production of
circulating estradiol and progesterone. Manufactured by Debiopharm
in Switzerland, this long-acting formulation is marketed and
distributed globally through regional licensees.
About Dexa Medica
PT Dexa Medica (member of Dexa Group) is a leading Indonesian
research-based pharmaceutical company, which was established on
September 27th, 1969. Starting with the export of pharmaceutical
products created by Indonesian scientists in 1993, now Dexa Medica
has exported pharmaceutical products to 4 continents: Africa,
America, Asia and Europe. Regarding the export of pharmaceutical
products, Dexa Medica has become a pioneer in Indonesian
pharmaceutical manufacturers entering the UK and was awarded the
Primaniyarta Award from the Indonesian government in 2017, 2018,
and 2019. (continues)